#USA #Palo Alto #Kodiak Sciences #KSI-101 #Zenkuda

Kodiak Sciences Q3 2026 Business Highlights and Financial Summary

Kodiak Sciences Inc., listed on Nasdaq under the symbol KOD, has shared its significant business highlights and financial outcomes for Q3 2026, concluding on September 30. CEO Victor Perlroth, M.D., expressed confidence in the company's leading position in the retinal medicine sector, particularly with three late-stage assets poised for impactful advancements.

Highlights from the Quarter

1. Promising Clinical Results: The company's lead product, Zenkuda (tarcocimab tedromer), achieved important milestones during the Phase 3 DAYBREAK study. It met all primary endpoints, demonstrating substantial vision improvements and a 24-week treatment regimen for many patients. These results indicate Zenkuda's potential to emerge as a first-line therapy for wet age-related macular degeneration (AMD).

2. Progress on Tabirafusp-ted: This innovative therapy has also shown positive outcomes in the Phase 3 trials, as it continues to enroll participants for the ALTO study, aimed at diabetic macular edema. The results have reinforced confidence in the treatment's efficacy and safety, crucial for addressing the challenges of retinal vascular diseases.

3. Upcoming Milestones: The company anticipates sharing the first Phase 3 results for KSI-101 in December 2026, directed toward impacting patients suffering from macular edema due to inflammation. Following successful outcomes, Kodiak plans to file for a Biologics License Application (BLA) for KSI-101 in Q2 2027.

Financial Snapshot

• - Cash and Cash Equivalents: As of the end of Q3 2026, Kodiak reported a robust cash position of $88.7 million. The company believes its current financial resources will sustain operations throughout 2027.
• - R&D and G&A Expenses: Research and development costs rose to $58.3 million, reflecting increased clinical activities. General and administrative expenses decreased to $8.8 million, largely due to a one-time benefit from a lease termination.
• - Net Loss: Kodiak’s net loss for Q3 stood at $66.2 million, compared to $61.5 million for the same period in 2025. This net loss includes significant non-cash compensation expenses.

Future Outlook

Dr. Perlroth highlighted the exciting journey ahead for Kodiak, emphasizing its strategy to enhance treatment options for retinal specialists while addressing significant unmet needs in retinal diseases. The upcoming BLA submissions and ongoing studies are set to bring new therapies that could dramatically improve patient outcomes. Kodiak's innovative approach, specifically its unique ABC platform, positions it strongly in the competitive landscape of retinal treatments.

Conclusion

As Kodiak Sciences prepares for the next stages in their clinical research and development, the data from the third quarter reflects a promising trajectory for the company and its pivotal retinal disease therapies. Investors and stakeholders alike will be keenly watching the upcoming results and applications expected in the following quarters.

For ongoing updates on Kodiak Sciences, visit Kodiak's Investor Relations Page.